Question explored with the scientific record
what about mcclobomide
I cannot find any evidence about "mcclobomide" in the records provided. The retrieved studies cover propafenone for arrhythmias, COVID-19 vaccines, mefloquine, cough medicines, cancer drugs, contrast agents, and other unrelated topics. None of them mention mcclobomide by name or test its effects.
The question asks about a drug I have no data on. Without a single study in the retrieval, I cannot assess its safety, efficacy, mechanism, or risk profile. That silence does not mean the drug is safe or unsafe. It means the retrieval did not surface any relevant information.
If you have a specific spelling or a different name for this substance, I can try again. As it stands, the evidence base here is empty for this question.
My call: no evidence was retrieved to answer this question. Confidence: not clear.
Sources used 18
-
Oral propafenone therapy for children with arrhythmias: Efficacy and adverse effects in midterm follow-up
This study evaluates the efficacy and safety of oral propafenone therapy in 57 children with various arrhythmias, finding it effective particularly in those with normal hearts, while noting a low incidence of adverse effects.
DOI: 10.1016/0002-8703(91)90467-v -
Safety of COVID‐19 vaccines
A cross-sectional survey of 1,736 adults in Iraq and Jordan assessed post-vaccination adverse effects after Pfizer-BioNTech, AstraZeneca, and Sinopharm vaccines, finding generally mild to moderate reactogenicity with Sinopharm showing comparatively fewer adverse effects and seve…
DOI: 10.1002/jmv.27214 -
Does mefloquine prophylaxis affect electroencephalographic patterns?
This study investigates the effects of mefloquine prophylaxis on electroencephalogram (EEG) patterns in healthy travelers, revealing no significant increase in abnormal EEGs but highlighting gender differences in drug serum levels and adverse effects.
DOI: 10.1016/s0002-9343(01)01065-8 -
The Latest Update on Over-the-Counter Cough and Cold Product Use in Children
This study reviews the safety and efficacy of over-the-counter cough and cold medications in children, highlighting the lack of evidence supporting their use and the associated risks of adverse effects.
DOI: 10.5863/1551-6776-14.3.127 -
Pathological characteristics and early post-hepatic-resection outcome of patients with hepatocellular carcinoma occurred after hepatitis C treatment with new direct-acting antivirals: a multicenter cohort study
This multicenter study evaluates the efficacy and safety of Regorafenib in treating hepatocellular carcinoma (HCC) in real-life settings, highlighting its impact on survival and the predictive value of dermatological adverse effects from prior treatment with Sorafenib.
DOI: 10.1016/S0168-8278(18)30248-4 -
Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib
This study reports on the adverse effects of the epidermal growth factor receptor inhibitor erlotinib, specifically facial hypertrichosis and trichomegaly, in three patients with metastatic lung adenocarcinoma, highlighting the need for awareness of such side effects in clinical…
DOI: 10.1016/j.jaad.2009.11.589 -
Complications in cerebral angiography
This study compares the adverse effects and complications of a new non-ionic contrast medium, iohexol, with an ionic medium, meglumine metrizoate, in 100 patients undergoing cerebral angiography, finding that iohexol is better tolerated despite minor subjective adverse effects w…
DOI: 10.1007/BF00455735 -
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
This meta-analysis evaluates the safety and efficacy of durvalumab (MEDI4736), a PD-L1 inhibitor, in various solid tumors, finding it to be safe with manageable adverse effects and improved prognosis associated with higher PD-L1 expression.
DOI: 10.2147/dddt.s162214 -
Pharmacokinetic and Safety Evaluation of Lurasidone in Pediatric Patients with Psychiatric Disorders
This study evaluates the pharmacokinetics and safety of lurasidone in pediatric patients aged 6 to 17 with various psychiatric disorders, identifying a tolerated dose range and common adverse effects.
DOI: 10.1016/s0924-9338(15)30944-5 -
1111 THE LIVER EXHIBITS THERMAL VARIATIONS DEPENDING ON THE FIBROSIS DEGREE: A PROOF OF CONCEPT CONCERNING THE USE OF DIFFERENTIAL SCANNING CALORIMETRY FOR ASSESSING LIVER FIBROSIS
This study investigates the therapeutic efficacy of RNA interference targeting liver Bid to suppress fibrosis associated with Nonalcoholic Steatohepatitis (NASH), demonstrating significant improvements in liver fibrosis markers and suggesting potential for RNAi as an antifibroti…
DOI: 10.1016/s0168-8278(13)61112-5 -
N-Glycan Fingerprinting of the NIST monoclonal antibody (NISTmAb)
This study presents a comprehensive glycan fingerprinting method for the NIST monoclonal antibody (NISTmAb) and Humira®, revealing critical insights into their glycosylation profiles and implications for therapeutic efficacy.
DOI: 10.1101/2025.02.15.638459 -
The Role of Thickening Agent Proportions in Optimizing Nanoemulsion Gel for Dermatophytosis Treatment
This study investigates the impact of varying proportions of Carbomer 940 as a thickening agent in nanoemulsion gels containing α-pinene on the transdermal delivery and therapeutic efficacy against dermatophytosis caused by Trichophyton rubrum, demonstrating that a moderate prop…
DOI: 10.2147/IJN.S479514 -
Efficiency of molar distalization associated with second and third molar eruption stage
This systematic review evaluates the efficiency of molar distalization in relation to the eruption stages of the second and third molars, finding minimal clinically significant effects based on low-level evidence clinical trials.
DOI: 10.2319/081612-658.1 -
Bioresorbable scaffolds: Current knowledge, potentialities and limitations experienced during their first clinical applications
This 2012 review surveys bioresorbable scaffolds (BRS) in coronary revascularization, detailing their potential advantages over permanent metal stents, the clinical trial evidence to date, device designs, and the limitations/risks encountered during early clinical use.
DOI: 10.1016/j.ijcard.2012.05.093 -
Individualized mRNA Vaccines in Melanoma—Where Do We Stand?
A comprehensive review of individualized mRNA vaccines for melanoma, detailing the mechanism, lipid nanoparticle delivery, tumor/host neoantigen targeting (INT/V940), current clinical trial evidence, safety considerations, and future challenges and opportunities for broader canc…
DOI: 10.3390/vaccines13090986 -
Role of muscarinic antagonists in asthma therapy
A comprehensive narrative review of muscarinic antagonists (SAMAs and LAMAs) in asthma, detailing pharmacology, preclinical mechanisms, and clinical trial evidence that supports tiotropium as add-on therapy in various asthma populations, its potential anti-inflammatory/remodelin…
DOI: 10.1080/17476348.2017.1289844 -
Identification and description of controlled clinical trials published in Physiotherapy journals in S pain
This study identifies and describes controlled clinical trials (CCTs) published in Spanish physiotherapy journals, revealing a limited number of trials with a high risk of bias and emphasizing the necessity of handsearching due to the lack of indexing in major databases.
DOI: 10.1111/jep.12441 -
Metabolic Surgery for Type 2 Diabetes: Appraisal of Clinical Evidence and Review of Randomized Controlled Clinical Trials Comparing Surgery with Medical Therapy
This study reviews the clinical evidence and randomized controlled trials comparing metabolic surgery to medical therapy for type 2 diabetes, highlighting the potential benefits and significant complications associated with surgical interventions.
DOI: 10.1007/s11883-013-0376-y